Jak2 Inhibitor Compounds Selective Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Jak2 inhibitor compounds lack target specificity, leading to side effects and reduced efficacy in treating Jak2-mediated disorders.
Innovation Solution
Development of compounds such as 2-(diethylaminomethyl)-4-[4-[3-(diethylaminomethyl)-4-hydroxy-phenyl]hex-3-en-3-yl]phenol (G6) and its derivatives, which selectively inhibit Jak2 kinase activity with minimal effect on c-Src or Tyk2 autophosphorylation, for use in treating Jak2-mediated disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing Jak2 inhibitor compounds are used, then Jak2 kinase activity is blocked, but target specificity is reduced leading to side effects
Solution Approach 1:
The patent applies local quality by designing compound G6 with specific molecular features (diethylaminomethyl groups, hydroxy-phenyl groups, and a 3-en-3-yl linker) that create localized interactions with the Jak2 binding pocket. These structural modifications enable the compound to selectively bind to Jak2 while avoiding off-target kinases, thus achieving both efficacy and specificity.
Solution Approach 2:
The patent employs parameter changes by optimizing the chemical structure of Jak2 inhibitors, specifically modifying the R1, R2, and R3 substituents on the phenyl rings and adjusting the linker chain length and unsaturation. These parameter optimizations enhance binding affinity for Jak2 while reducing cross-reactivity with other kinases, resolving the contradiction between inhibition efficacy and target specificity.
2Productivity
If Jak2 inhibitor compounds are developed for therapeutic use, then Jak2-mediated disorders can be treated, but selectivity limitations reduce therapeutic efficacy
Solution Approach 1:
The compound G6 incorporates specific functional groups (diethylaminomethyl at positions 1 and 3, hydroxy-phenyl at position 4) that create a unique binding profile for Jak2. These localized structural features enable selective inhibition of Jak2-mediated signaling pathways involved in erythroleukemia while sparing other kinase pathways, thereby improving therapeutic efficacy without compromising selectivity.
3Object-affected harmful factors
If compounds are designed to selectively inhibit Jak2, then target specificity is improved, but maintaining aqueous solubility becomes challenging
Solution Approach 1:
The patent applies parameter changes by modifying the solubility characteristics of compound G6 through the inclusion of polar functional groups (hydroxy groups on phenyl rings, tertiary amine groups in diethylaminomethyl substituents). These parameter adjustments maintain the compound's selective binding to Jak2 while improving its aqueous solubility to enable effective delivery and pharmacokinetics.
Data Source
AI summary
The invention relates to kinase inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating disorders, especially cancer.